Proliferation of ADSCs in medium dedicated for MSCs - Pico Green assay

8th World Biomaterials Congress 200831496

Characterization and Culturing of Adipose-Derived Precursor Cells

10.1002/9780470454923.ch24Emerging Technology Platforms for Stem Cells439-46

ERP Shape+colour repetition effects.

<p>(a) Grand average ERPs to same (red line) versus change (black line) stimuli plotted between −100 and 500 msec, with respective topographies for the P2 at peak amplitude; (b) topography associated with the difference in mean amplitude for the same versus change contrast over the highlighted 40 msec epoch for the P2; (c) mean amplitudes across posterior electrode clusters during the P2 as a function of laterality and transformation.</p

ERP Colour effects.

<p>Grand average ERPs to correctly (black line) and incorrectly (red line) coloured objects plotted between −100 and 800 msec with (a) topography associated with the peak amplitude for correctly versus incorrectly coloured objects for the P2; and (b) topography associated with the peak amplitude for correctly versus incorrectly coloured objects for the P3.</p

ERP Shape repetition effects.

<p>(a) Grand average ERPs to new (blue line) versus change (black line) stimuli plotted between −100 and 500 msec, with respective topographies for the N1 at peak amplitude; (b) topography associated with the difference in mean amplitude for the new versus change contrast over the highlighted 40 msec epoch for the N1; (c) mean amplitudes across posterior electrode clusters during the N1 as a function of laterality and transformation.</p

Mean response times (msec) and percentage correct (%) for the coloured-object decision test; values in brackets represent standard error.

<p>Mean response times (msec) and percentage correct (%) for the coloured-object decision test; values in brackets represent standard error.</p

A randomized trial of progesterone in women with recurrent miscarriages

BACKGROUND Progesterone is essential for the maintenance of pregnancy. However, whether progesterone supplementation in the first trimester of pregnancy would increase the rate of live births among women with a history of unexplained recurrent miscarriages is uncertain. METHODS We conducted a multicenter, double-blind, placebo-controlled, randomized trial to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage. We randomly assigned women with recurrent miscarriages to receive twicedaily vaginal suppositories containing either 400 mg of micronized progesterone or matched placebo from a time soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) through 12 weeks of gestation. The primary outcome was live birth after 24 weeks of gestation. RESULTS A total of 1568 women were assessed for eligibility, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women). The follow-up rate for the primary outcome was 98.8% (826 of 836 women). In an intention-to-treat analysis, the rate of live births was 65.8% (262 of 398 women) in the progesterone group and 63.3% (271 of 428 women) in the placebo group (relative rate, 1.04; 95% confidence interval [CI], 0.94 to 1.15; rate difference, 2.5 percentage points; 95% CI, −4.0 to 9.0). There were no significant between-group differences in the rate of adverse events. CONCLUSIONS Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with a history of unexplained recurrent miscarriages. (Funded by the United Kingdom National Institute of Health Research; PROMISE Current Controlled Trials number, ISRCTN92644181.)A. Coomarasamy, B.W. Mo